Literature DB >> 9521062

The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb.

W G Ferlin1, T von der Weid, F Cottrez, D A Ferrick, R L Coffman, M C Howard.   

Abstract

A protective immune response to the intracellular parasite Leishmania major requires the development of a Th1 CD4+ T cell phenotype. We demonstrate herein that BALB/c mice, which normally develop a susceptible Th2 response to L. major infection, are protected when co-injected with an agonistic anti-murine CD40 mAb. Anti-CD40 mAb-mediated protection in this system was found to be T cell dependent, since it was not observed in C57BL/6 x 129 mice that were rendered T cell deficient (TCR beta-/- x TCR delta-/-) and L. major susceptible. Anti-CD40 mAb stimulation of L. major-infected BALB/c mice was accompanied by increased IL-12 and IFN-gamma production in draining lymph nodes, analyzed either by direct expression, or in an antigen-specific in vitro recall assay. The protective role of these cytokines was indicated by the finding that anti-CD40 mAb-mediated protection of L. major-infected BALB/c mice could be reversed by co-treating the animals with neutralizing anti-IL-12 and/or anti-IFN-gamma mAb. Collectively, these data suggest that BALB/c mice develop a protective Th1 CD4+ T cell response to L. major infection when co-injected with anti-CD40 mAb. While the CD40-CD40L interaction has been previously shown to be vital in the control of murine Leishmaniasis, the current study establishes in vivo that anti-CD40 mAb treatment alone is sufficient to protect BALB/c mice from L. major infection and raises the possibility of utilizing this approach for vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521062     DOI: 10.1002/(SICI)1521-4141(199802)28:02<525::AID-IMMU525>3.0.CO;2-M

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

3.  Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin.

Authors:  S Jolles; J Christensen; M Holman; G B Klaus; A Ager
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

4.  Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice.

Authors:  I B Kremer; M P Gould; K D Cooper; F P Heinzel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Influence of costimulatory molecules on immune response to Leishmania major by human cells in vitro.

Authors:  C I Brodskyn; G K DeKrey; R G Titus
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 6.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

7.  NF-kappaB is involved in regulation of CD40 ligand expression on Mycobacterium bovis bacillus Calmette-Guérin-activated human T cells.

Authors:  Patricia Méndez-Samperio; Hilda Ayala; Abraham Vázquez
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

8.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

9.  In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni.

Authors:  James P Hewitson; Paul A Hamblin; Adrian P Mountford
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

10.  The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation.

Authors:  Meghan A Koch; Glady's Tucker-Heard; Nikole R Perdue; Justin R Killebrew; Kevin B Urdahl; Daniel J Campbell
Journal:  Nat Immunol       Date:  2009-05-03       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.